Allspring Global Investments Holdings LLC Raises Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Allspring Global Investments Holdings LLC raised its holdings in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 23.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,313 shares of the company’s stock after buying an additional 7,573 shares during the period. Allspring Global Investments Holdings LLC owned about 0.07% of Voyager Therapeutics worth $223,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Empowered Funds LLC lifted its stake in shares of Voyager Therapeutics by 5.3% in the 4th quarter. Empowered Funds LLC now owns 47,206 shares of the company’s stock valued at $268,000 after acquiring an additional 2,397 shares during the last quarter. SG Americas Securities LLC grew its position in Voyager Therapeutics by 86.7% during the 4th quarter. SG Americas Securities LLC now owns 23,044 shares of the company’s stock worth $131,000 after acquiring an additional 10,704 shares during the last quarter. Barclays PLC increased its stake in Voyager Therapeutics by 55.8% in the 3rd quarter. Barclays PLC now owns 104,462 shares of the company’s stock worth $612,000 after purchasing an additional 37,398 shares during the period. Geode Capital Management LLC lifted its position in Voyager Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock valued at $6,316,000 after purchasing an additional 6,740 shares during the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of Voyager Therapeutics during the third quarter valued at approximately $6,192,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research note on Monday, January 27th. Cantor Fitzgerald started coverage on Voyager Therapeutics in a research report on Friday, January 10th. They set an “overweight” rating and a $5.73 price target for the company. Citigroup assumed coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, Wedbush restated an “outperform” rating and set a $9.00 target price (down previously from $11.00) on shares of Voyager Therapeutics in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $15.72.

Voyager Therapeutics Trading Up 0.5 %

Shares of NASDAQ:VYGR opened at $4.12 on Wednesday. The stock has a fifty day simple moving average of $5.28 and a two-hundred day simple moving average of $6.05. The stock has a market capitalization of $225.06 million, a price-to-earnings ratio of 5.80 and a beta of 0.91. Voyager Therapeutics, Inc. has a 12-month low of $4.00 and a 12-month high of $10.66.

Insider Buying and Selling at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now owns 112,328 shares in the company, valued at $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 10,778 shares of company stock worth $58,548. Company insiders own 4.53% of the company’s stock.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.